Showing papers in "Thrombosis Research in 1985"

TL;DR: Thrombi in TTP are essentially platelet thrombi and that subendothelial hyaline deposits may not be a result of increased vascular permeability but may be platelets incorporated into the arterial wall and covered with newly formed endothelial cells.

TL;DR: It is concluded that additional administration of heparin does not improve the effect of AT III substitution in patients with DIC and that side effects such as thrombocytopenia and an increased blood loss are likely to develop when both substances are given simultaneously.

TL;DR: Changes in fibrinolysis, platelets and coagulation during hypothermia were investigated in anesthetized dogs and the tendency towards shortening of the recalcification time was not related to the core temperature.

TL;DR: It is shown that tissue factor markedly accelerates the conversion of factor VII to factor VIIa, indicating that this essential coagulation cofactor is clearly bifunctional.

TL;DR: The presence of Factor XIII subunit a was demonstrated in human monocytes by immunoperoxidase staining using specific antisera against Factor XIII and its subunits and this finding was verified by immunobiochemical techniques, as well.

TL;DR: A supplement of MaxEPA oil containing 5 g of omega-3 polyunsaturated fatty acids was given for two weeks to nine normal volunteers and there was a fall in the levels of inhibitors of vascular plasminogen activator (VPA), but no significant changes occur in serum cholesterol, triglycerides, HDL or LDL levels.

TL;DR: The data demonstrate that the major proteins of HDL - apo AI and apo AII - and possibly certain minor constituent(s) common to HDL and VLDL participate in the fibrinolytic process.

TL;DR: The studies suggest that the collagen-stimulated release of PF1 and PF3 is not coupled to either platelet aggregation or PF4 release but is probably a separate phase of the release reaction.

TL;DR: Although the balance of evidence is that the plasma fibrinogen level enhances aggregability, these conflicting results emphasize the limitation of any simple concept of "platelet aggregability".

TL;DR: From this material, fractions corresponding to the HMW, LMW and LMW' fibrinogen fractions of plasma were obtained by step-wise precipitation with ammonium sulfate by precipitation with beta-alanine in the presence of citrate and protease inhibitors.

TL;DR: The membrane-associated factor V-like activity and the phospholipid-like catalytic surface activity were studied in human platelets from normal and twofactor V-deficient donors to view PF1 and PF3 to be activities associated with membranous vesicles released from platelets only after stimulation.

TL;DR: Results suggest that in human endothelial cells, histamine, thrombin and ionophore A23187 directly or indirectly activated both phospholipase C and phospholIPase A2 and these activations most likely involve mobilization of Ca2+.

TL;DR: Electro-immunoassays performed with the use of poly- and monoclonal antibodies to the protein revealed that it binds to thrombin-anti-thrombin III (T X AT-III) to form stable S X T XAT-III complexes, which could emerge as a novel component of the blood coagulation system in the future.

TL;DR: It may be possible to obtain preventive effect on thrombus formation with a heparin fragment, as there was a correlation between the XaI activity of the differentHeparin fragments and frequency of thrombosis.

TL;DR: Improved thrombolysis with t-PA with minimal bleeding side-effects is achieved in rabbits when t- PA is administered in a relatively high dose given over a short period of time.

TL;DR: It is concluded that activated protein C accelerates whole blood or plasma-leukocyte clot lysis by modulating activation of the plasminogen system by metabolically active leukocytes.

TL;DR: It is concluded that in coronary heart disease patients there is a defective fibrinolytic activity probably due to an increase in tissue-plasminogen activator inhibitor.

TL;DR: The distribution, and clearance of the tissue plasminogen activator (tPA) was studied in rabbits, rats and mice and the increase in the half-life of tPA in hepatectomized rabbits resulted in an improved thrombolytic effect after treatment with 0.5 mg tPA.

TL;DR: Both the co-chromatography of this unknown phospholipid and the increase in 32p-PI in gel-filtered platelets can explain the difference in32p-labelling in phosphoinositides reported in the literature.

TL;DR: P perturbation of endothelial cells by treatment with phorbol ester or endotoxin induces potent tissue factor procoagulant activity, which appears to require protein and RNA synthesis, normal cytoskeletal functions, and the Ca++-calmodulin system.

TL;DR: Differences between normal platelet and plasma vWf are shown, and platelet size must be considered when platelet vWF is measured in disease states, and it is suggested that plateletsize must be considering when Platelet von Willebrand factor is measured during disease states.

TL;DR: In intra-arterial infusion of prostacyclin promotes healing of ischemic ulcers in non-diabetic patients with peripheral arterial disease without gangrene.

TL;DR: It is concluded thatactivated protein C facilitates fibrinolysis by preventing inhibition of plasminogen activators and may be a mechanism by which activated protein C increases fibralelytic activity in vivo.

TL;DR: It is concluded that these LMWH's are as effective as SH in preventing extension of established thrombosis and there was no correlation between the antithrombotic effect and the anticoagulant effects.

TL;DR: A congenital, probably homozygous deficiency of protein C combined with a heterozygous molecular abnormality of plasminogen was found in a 21-year-old male who had been suffering from recurrent venous thrombosis since the age of 14.

TL;DR: A monoclonal antibody named TM60, which inhibited both thrombin- and ristocetin-induced platelet aggregations, was obtained by hybridoma technique and it was demonstrated that TM60 recognized an epitope on GPIb whose molecular weight was 165,000 under non-reduced and 145,000under reduced conditions.